[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.241.199. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
March 4, 2009

5-α Reductase Inhibitors and Risk of Hip Fracture—Reply

JAMA. 2009;301(9):935. doi:10.1001/jama.2009.183

In Reply: In response to Dr Bollu and colleagues, the duration of use of finasteride was highly correlated with total dose. The median (25th-75th percentile) time from first prescription to fracture/index date was 1.6 years (0.8-3.7 years) for case patients and 2.1 years (0.9-3.8 years) for control patients. When stratified by time since first prescription for finasteride (overall median), the inverse relationship with hip fracture was fairly consistent across categories of cumulative dose among men with more remote first prescriptions (odds ratio [OR], 0.61; 95% confidence interval [CI], 0.31-1.19; OR, 0.69; 95% CI, 0.37-1.26; and OR, 0.54; 95% CI, 0.25-1.15 for men with cumulative doses of 10-500 mg, 501-2750 mg, and ≥2751 mg, respectively). For men with more recent first prescriptions, the relationship was attenuated with larger cumulative doses (OR, 0.68; 95% CI, 0.38-1.22; OR, 1.17; 95% CI, 0.69-1.99; and OR, 1.66; 95% CI, 0.32-10.69 for men with cumulative doses of 10-500 mg, 501-2750 mg, and ≥2751 mg, respectively), but the estimates were unstable due to the small numbers of men with both large doses and recent prescriptions.

First Page Preview View Large
First page PDF preview
First page PDF preview
×